Literature DB >> 31027552

Human Immunodeficiency Virus in Transgender Persons.

Cassie G Ackerley1, Tonia Poteat2, Colleen F Kelley3.   

Abstract

Worldwide, transgender populations are disproportionately affected by human immunodeficiency virus (HIV). Pervasive stigma and discrimination impact social and economic determinants of health, which perpetuate HIV disparities among transgender individuals. This article reviews the prevalence of HIV infection among transgender populations and presents psychosocial, behavioral, and individual level factors that contribute to HIV acquisition. The authors provide practical recommendations regarding a patient-centered approach to HIV/sexually transmitted infection risk assessment. The role of preexposure prophylaxis utilization in preventing the transmission of HIV is discussed as well as the current data on HIV treatment outcomes for transgender people living with HIV.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gender identity; HIV; HIV care continuum; Hormone therapy; Preexposure prophylaxis; Sexual risk behavior; Sexually transmitted infections; Transgender

Mesh:

Substances:

Year:  2019        PMID: 31027552     DOI: 10.1016/j.ecl.2019.02.007

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  2 in total

1.  Disparities in the PrEP continuum for trans women compared to MSM in San Francisco, California: results from population-based cross-sectional behavioural surveillance studies.

Authors:  Erin C Wilson; Caitlin M Turner; Sean Arayasirikul; Marguerita Lightfoot; Susan Scheer; Henry F Raymond; Albert Liu
Journal:  J Int AIDS Soc       Date:  2020-06       Impact factor: 5.396

2.  HIV and STI positivity rates among transgender people attending two large STI clinics in the Netherlands.

Authors:  Susanne Drückler; Ceranza Daans; Elske Hoornenborg; Henry De Vries; Martin den Heijer; Maria Prins; Sophie Kuizenga Wessel; Martijn van Rooijen
Journal:  Sex Transm Infect       Date:  2021-04-19       Impact factor: 4.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.